Cargando…

Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are inflammatory diseases requiring long-term glucocorticoid treatment. Limited data on dynamics in leukocyte counts before, during and after treatment are available. Leukocyte counts were measured, as cellular markers of inflammation, at f...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Sleen, Yannick, Graver, Jacoba C., Abdulahad, Wayel H., van der Geest, Kornelis S. M., Boots, Annemieke M. H., Sandovici, Maria, Brouwer, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714037/ https://www.ncbi.nlm.nih.gov/pubmed/31507597 http://dx.doi.org/10.3389/fimmu.2019.01981

Ejemplares similares

Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica
por: Reitsema, Rosanne D., et al.
Publicado: (2023)

Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica
por: Reitsema, Rosanne D., et al.
Publicado: (2022)

Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis
por: van Sleen, Yannick, et al.
Publicado: (2019)

Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica
por: van Sleen, Yannick, et al.
Publicado: (2022)

Phenotypic, transcriptomic and functional profiling reveal reduced activation thresholds of CD8(+) T cells in giant cell arteritis
por: Reitsema, Rosanne D, et al.
Publicado: (2022)

Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica
por: van Sleen, Yannick, et al.
Publicado: (2022)

Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis
por: van Sleen, Yannick, et al.
Publicado: (2017)

Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica
por: van der Geest, Kornelis S M, et al.
Publicado: (2021)

A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL‐40/Interleukin‐13 Receptor α2 Axis
por: van Sleen, Yannick, et al.
Publicado: (2021)

Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica
por: van der Geest, Kornelis S. M., et al.
Publicado: (2022)

Distinct macrophage phenotypes skewed by local granulocyte macrophage colony‐stimulating factor (GM‐CSF) and macrophage colony‐stimulating factor (M‐CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis
por: Jiemy, William F, et al.
Publicado: (2020)

Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort
por: Esen, Idil, et al.
Publicado: (2023)

Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?
por: van der Geest, Kornelis S. M., et al.
Publicado: (2018)

Need and value of targeted immunosuppressive therapy in giant cell arteritis
por: Sandovici, Maria, et al.
Publicado: (2022)

Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica
por: van der Geest, Kornelis S M, et al.
Publicado: (2022)

Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment
por: Esen, Idil, et al.
Publicado: (2021)

Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?
por: Carvajal Alegria, Guillermo, et al.
Publicado: (2023)

Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022)

Massive B-Cell Infiltration and Organization Into Artery Tertiary Lymphoid Organs in the Aorta of Large Vessel Giant Cell Arteritis
por: Graver, Jacoba C., et al.
Publicado: (2019)

Evidence for increased interferon type I activity in CD8+ T cells in giant cell arteritis patients
por: van Nieuwland, Marieke, et al.
Publicado: (2023)

Optimal management of giant cell arteritis and polymyalgia rheumatica
por: Charlton, Rodger
Publicado: (2012)

Genetic epidemiology: Giant cell arteritis and polymyalgia rheumatica
por: Gonzalez-Gay, Miguel A
Publicado: (2001)

Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update
por: Nesher, Gideon, et al.
Publicado: (2016)

Liver involvement in polymyalgia rheumatica and giant cell arteritis
por: Hysa, Elvis, et al.
Publicado: (2020)

Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA
por: Hid Cadena, Rebeca, et al.
Publicado: (2019)

Giant cell arteritis with polymyalgia rheumatica on FDG‐PET/CT
por: Baba, Akira, et al.
Publicado: (2017)

Familial aggregation of longevity in giant cell arteritis and polymyalgia rheumatica
por: Milchert, Marcin, et al.
Publicado: (2020)

Predictive Factors of Giant Cell Arteritis in Polymyalgia Rheumatica Patients
por: Ramon, André, et al.
Publicado: (2022)

Giant Cell Arteritis Mimicking Polymyalgia Rheumatica: A Challenging Diagnosis
por: Ohta, Ryuichi, et al.
Publicado: (2022)

Metabolic bone health considerations in giant cell arteritis and polymyalgia rheumatica
por: Low, Candice, et al.
Publicado: (2023)

Impact of Aging on the Frequency, Phenotype, and Function of CD161-Expressing T Cells
por: van der Geest, Kornelis S. M., et al.
Publicado: (2018)

Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases
por: Pujades-Rodriguez, Mar, et al.
Publicado: (2016)

Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis
por: Emamifar, Amir, et al.
Publicado: (2021)

Polymyalgia Rheumatica
por: Dixon, A. St J.
Publicado: (1969)

Polymyalgia rheumatica
por: Rosenberg, Hans, et al.
Publicado: (2021)

Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis
por: Rondaan, Christien, et al.
Publicado: (2017)

A Case of Clinical Uncertainty Solved: Giant Cell Arteritis with Polymyalgia Rheumatica Swiftly Diagnosed with Long Axial Field of View PET
por: Nienhuis, Pieter H., et al.
Publicado: (2022)

Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?
por: Toussirot, Éric, et al.
Publicado: (2016)

Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis
por: Smutny, Tomas, et al.
Publicado: (2019)

The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population
por: Yates, Max, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8gsr6fi1vqrqotk9me80pfpt9k